The effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency department

Investigation of the effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency department

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101020004976N6

Enrollment

Registered

2020-07-18

Start date

2020-05-14

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: In this group, patients will receive a Lactocare® synbiotice capsule daily for a month. Intervention 2: Control group: Patients in this group will receive a capsule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Being a member of the personnel (including physicians and nurses) of the emergency department of Imam Reza hospital Active presence in the wards where patients with COVID-19 are hospitalized

Exclusion criteria

Exclusion criteria: History of clinical or laboratory diagnosis with COVID-19

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Before during and after treatment. Method of measurement: Thermometer.;Findings of CT scan and CXR. Timepoint: After treatment. Method of measurement: CT scan and CXR machines.;Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical tests.;WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical tests.;Infection by COVID-19. Timepoint: Before treatment, during treatment if symptoms appear and at the end of treatment. Method of measurement: PCR and antibody tests.;Cough and sore throat. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations.;Nausea, vomiting and diarrhea. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations.	—

Measure

Time frame

Fever. Timepoint: Before during and after treatment. Method of measurement: Thermometer.;Findings of CT scan and CXR. Timepoint: After treatment. Method of measurement: CT scan and CXR machines.;Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical tests.;WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical tests.;Infection by COVID-19. Timepoint: Before treatment, during treatment if symptoms appear and at the end of treatment. Method of measurement: PCR and antibody tests.;Cough and sore throat. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations.;Nausea, vomiting and diarrhea. Timepoint: Before, during and after treatment. Method of measurement: Clinical observations.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Ahanchian

Mashhad University of Medical Sciences

ahanchianh@mums.ac.ir+98 51 3801 2469

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026